CNTX-3001
Phase 1Small molecule
CNTX-3001 is one of 45 small molecule programs targeting Low back pain. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
237 competitors in Low Back Pain
#DrugCompanyPhaseTrials
1Sympazan
LundbeckPhase 3
Tofranil
SanofiPhase 3
Arcoxia
NovartisPhase 3
Suboxone
IIndivior Inc.
Phase 3
Pred Forte
NovartisPhase 3
Tylenol
KKenvue Brands
Phase 3
Keterol
PPamukkale University
Phase 3
Anjeso
Boehringer IngelheimPhase 3
Tanezumab
PfizerPhase 3
Xylocaine
MMEDRx USA, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CNTX-3001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCentrexion Therapeutics